{"id":296233,"date":"2025-05-06T00:00:00","date_gmt":"2025-05-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0012-2023-biopharma-systemic-lupus-erythematosus-unmet-need-unmet-need-lupus-nephritis-us-eu\/"},"modified":"2026-03-31T10:26:24","modified_gmt":"2026-03-31T10:26:24","slug":"unneim0012-2025-biopharma-systemic-lupus-erythematosus-unmet-need-unmet-need-lupus-nephritis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0012-2025-biopharma-systemic-lupus-erythematosus-unmet-need-unmet-need-lupus-nephritis-us-eu\/","title":{"rendered":"Systemic Lupus Erythematosus &#8211; Unmet Need &#8211; Unmet Need &#8211; Lupus Nephritis (US\/EU)"},"content":{"rendered":"<p>Renal inflammation associated with systemic lupus erythematosus (<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>), also known as lupus nephritis (<abbr title=\"lupus nephritis\">LN<\/abbr>), is among the most serious manifestations of the disease. Until 2020, no therapy was specifically approved for <abbr title=\"lupus nephritis\">LN<\/abbr>. Most treatments are old, genericized, and off-label, owing to the difficulty of developing novel treatments for this complex disease. In December 2020, the <abbr title=\"Food and Drug Administration\">FDA<\/abbr> granted a label extension for GlaxoSmithKline\u2019s Benlysta, making it the first drug to gain approval for the treatment of active <abbr title=\"lupus nephritis\">LN<\/abbr>. In January 2021, Aurinia\u2019s Lupkynis was granted <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval for the same patient population. Despite these recent approvals, unmet need remains high in this indication, leaving significant commercial opportunity for novel <abbr title=\"lupus nephritis\">LN<\/abbr> therapies.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals for active <abbr title=\"lupus nephritis\">LN<\/abbr>?<\/li>\n<li>Which clinical and nonclinical drug attributes are key influencers, which have limited impact, and which are hidden opportunities in the treatment of active <abbr title=\"lupus nephritis\">LN<\/abbr>?<\/li>\n<li>How do rheumatologists and nephrologists rate current therapies in terms of their performance on key treatment drivers and goals for active <abbr title=\"lupus nephritis\">LN<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in the treatment of active <abbr title=\"lupus nephritis\">LN<\/abbr>?<\/li>\n<li>What trade-offs across key drug attributes and price are acceptable to physicians for a hypothetical new drug for <abbr title=\"lupus nephritis\">LN<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature:<\/strong><\/p>\n<p>The Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<p><strong>Markets covered: <\/strong>United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 30 U.S. and 30 European rheumatologists, and 30 U.S. nephrologists fielded in March 2025<\/p>\n<p><strong>Key companies: <\/strong>GlaxoSmithKline, AstraZeneca, Genentech, Sandoz, Sanofi<\/p>\n<p><strong>Key drugs: <\/strong>Benlysta (<abbr title=\"intravenous\">IV<\/abbr> &#038; <abbr title=\"subcutaneous\">SC<\/abbr>), Rituxan \/ MabThera, Lupkynis, CellCept, hydroxychloroquine, mycophenolate mofetil<\/p>\n","protected":false},"template":"","class_list":["post-296233","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-systemic-lupus-erythematosus","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296233\/revisions"}],"predecessor-version":[{"id":575793,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296233\/revisions\/575793"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}